HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC)

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Human epidermal growth factor receptor 2 (HER2/ERBB2) is an oncogenic driver in non-small cell lung cancer (NSCLC).
• HER2 alterations in NSCLC include exon 20 activating mutations, gene amplification, and protein overexpression, with distinct biological effects and predictive values.
• HER2 mutations, particularly exon 20 insertions, represent a primary oncogenic mechanism in NSCLC.

Purpose of the Study:

• To review the role of HER2 as an oncogenic driver in NSCLC.
• To discuss current and emerging diagnostic methods for HER2 alterations in NSCLC.
• To summarize the evolving landscape of HER2-targeted therapies for NSCLC.

Main Methods:

• Review of scientific literature on HER2 in NSCLC.
• Next-Generation Sequencing (NGS) for mutation identification.
• Immunohistochemistry (IHC) and in situ hybridization for expression assessment.

Main Results:

• First-line treatment for advanced HER2-positive, non-squamous NSCLC involves platinum-based chemotherapy, with or without immunotherapy.
• HER2-targeted antibody-drug conjugates (ADCs) like Trastuzumab-Deruxtecan and Ado-Trastuzumab Emtansine show clinical benefit post-progression.
• Novel HER2-selective tyrosine kinase inhibitors (TKIs) and next-generation ADCs are demonstrating promising efficacy, including in pre-treated patients.

Conclusions:

• Advances in HER2 diagnostics are crucial for identifying NSCLC patient populations.
• Emerging targeted therapies, including ADCs and TKIs, are expanding treatment options for HER2-altered NSCLC.
• Personalized treatment strategies are becoming increasingly important for managing HER2-driven NSCLC.